ClinicalTrials.gg

Program

MDR-001

A development code.

Its studies are mostly in Obesity · Overweight · Lymphoma, Follicular, led by MindRank AI.

Furthest: phase 3, since Nov 18, 20256 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MindRank AI65 open or runningphase 3since Nov 18, 2025Sep 16, 2024Jun 2027phase 3 · NCT07274137

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2024First study: phase 2 study in ObesityFirst studyNCT06606483 · 300 planned · China
  2. Jan 7, 2025Phase 2 study in OverweightNCT06778850 · 128 enrolled · China
  3. Jul 23, 2025Phase 1 study in ObesityNCT07110766 · 24 planned · China
  4. Nov 18, 2025Phase 3 study in OverweightPhase 3 reachedNCT07274137 · 738 planned · China
  5. Apr 11, 20262 phase 1 studiesNCT07550634, NCT07550621

Ahead

  1. Jun 2027Primary completion: phase 3 study in OverweightNCT07274137

TargetBeta

GLP1R →read by rule
“A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and to matched healthy controls.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07550634Lymphoma, Follicular · China1Not yet recruitingJul 8, 202632
NCT07550621Healthy Volunteers (HV) · China1Not yet recruitingMay 31, 202628
NCT07274137Overweight · China3Not yet recruitingJun 2027738
NCT07110766Obesity · China1Not yet recruitingSep 15, 202524
NCT06778850Overweight · China2CompletedJul 15, 2024128
NCT06606483Obesity · China2Not yet recruitingJul 30, 2025300

How it is read

Names in the registry

  • “MDR-001”, 6 entries

Codes read as this program: MDR001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.